{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-125317","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.714395+00:00","generated_at":"2026-06-21T07:35:24.222034+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Entrada licenses DM1 program to Vertex for $224M upfront, $26M equity, up to $485M milestones","bullets":["Upfront payment of ~$224M plus $26M equity investment; potential milestones up to $485M and tiered mid-to-high single-digit royalties on net sales.","Vertex gets exclusive worldwide license to ENTR-701 (late-stage preclinical) and other EEV-based DM1 candidates under 4-year research collaboration.","Entrada will continue pre-clinical work funded by Vertex; Vertex handles global development, manufacturing, commercialization.","Deal subject to HSR antitrust clearance; proceeds extend Entrada's cash runway into H2 2025.","Vertex agrees to purchase 1,618,613 shares at $16.26/share (105% of VWAP) in private placement; 2-year lockup with partial release after 18 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-125317","json":"https://secwatch.observer/filing/0001104659-22-125317.json","markdown":"https://secwatch.observer/filing/0001104659-22-125317.md","text":"https://secwatch.observer/filing/0001104659-22-125317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922125317/0001104659-22-125317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922125317/tm2232230d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:35:24.222034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7897507190f04c7ab69933a2f78dab0afb077224","claim":"Entrada Therapeutics, Inc. entered into Strategic Collaboration and License Agreement with Vertex Pharmaceuticals Incorporated valued at Upfront payment of $223.7 million and equity investment of $26.3 million; potential milestones up to (effective 2022-12-07).","evidence_excerpt":"Item 1.01. Entry into a Material Definitive Agreement. On December 7, 2022, Entrada Therapeutics, Inc. (the “Company”) and Vertex Pharmaceuticals Incorporated (“Vertex”) entered into a Strategic Collaboration and License Agreement (the “License Agreement”) pursuant to which the Company granted Vertex an exclusive worldwide license to research, develop, manufacture, commercialize ENTR-701, the Company’s intracellular Endosomal Escape Vehicle (“EEV”)-based therapeutic candidate for the treatment of myotonic dystrophy type 1 (“DM1”) that targets expanded CUG repeats in DM1 protein kinase (DMPK) mRNA transcripts, as well as any additional EEV-based therapeutic candidates that may be identified by the Company for the potential treatment of DM1 in the course of the parties’ global research collaboration. The License Agreement provides for a four-year global research collaboration under which Vertex will fund the Company’s continued pre-clinical development of ENTR-701, as well as additional","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922125317/0001104659-22-125317-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Vertex Pharmaceuticals Incorporated"},{"label":"Value","value":"Upfront payment of $223.7 million and equity investment of $26.3 million; potential milestones up to"},{"label":"Effective","value":"2022-12-07"}],"fact_type":"material_agreement"},{"claim_id":"e3c108d05a236f29e97c2b41d315a613b7c6d281","claim":"Entrada Therapeutics, Inc. entered into Stock Purchase Agreement with Vertex Pharmaceuticals Incorporated valued at Aggregate purchase price of approximately $26.3 million for 1,618,613 shares at $16.26 per share. (effective 2022-12-07).","evidence_excerpt":"Concurrently with the execution of the License Agreement, on December 7, 2022, the Company entered into a stock purchase agreement (the “Stock Purchase Agreement”) with Vertex, pursuant to which Vertex has agreed to purchase from the Company 1,618,613 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share, in a private placement transaction for an aggregate purchase price of approximately $26.3 million or $16.26 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922125317/0001104659-22-125317-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Vertex Pharmaceuticals Incorporated"},{"label":"Value","value":"Aggregate purchase price of approximately $26.3 million for 1,618,613 shares at $16.26 per share."},{"label":"Effective","value":"2022-12-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}